Vericel Corp (VCEL)

• Market cap: $1.51B
• 1 day: -9.66%
• 5 days: -4.33%
• 1 month: -17.35%
• 3 months: -27.66%
• 6 months: -36.93%
• Year to date: -45.53%
• 1 year: -32.27%
• 5 years: 58.17%
• 10 years: 820.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Employees: 357

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

489% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $336K

88% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 68

3.07% more ownership

Funds ownership: 106.58% [Q1] → 109.64% (+3.07%) [Q2]

3% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 35

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

1% less capital invested

Capital invested by funds: $2.38B [Q1] → $2.35B (-$35.5M) [Q2]

1% less funds holding

Funds holding: 274 [Q1] → 271 (-3) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $58
• Avg. target: $58
• High target: $58

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin

$58

Buy Maintained

1 Aug 2025